Identification of transcription factor-miRNA-lncRNA feed-forward loops in breast cancer subtypes

Previous studies have demonstrated that transcription factor-miRNA-gene feed-forward loops (FFLs) played important roles in tumorigenesis. However, the lncRNA-involved FFLs have not been explored very well. Understanding the characteristics of lncRNA-involved FFLs in breast cancer subtypes may be a key question with clinical implications. In this study, we firstly constructed an integrated background regulatory network. Then, based on mRNA, miRNA, and lncRNA differential expression, we identified 147, 140, 284, 1031 dysregulated FFLs for luminal A, luminal B, HER2+ and basal-like subtype of breast cancer, respectively. Importantly, the known breast cancer-associated lncRNAs and miRNAs were enriched in the identified dysregulated FFLs. Through merging the dysregulated FFLs, we constructed the regulatory sub-network for each subtype. We found that all sub-networks were enriched in the well-known cancer-related pathways, such as cell cycle, pathways in cancer. Next, we also identified potential prognostic FFLs for subtypes of breast cancer, such as the hsa-miR-182-5p_JUN_XIST in basal-like subtype. Finally, we also discussed the potential application of inferring the candidate drugs for breast cancer treatment through modulating the lncRNA expression in the dysregulated FFLs. Collectively, this study elucidated the roles of lncRNA-involved FFLs in breast cancer subtypes, which could contribute to understanding breast cancer pathogenesis and improving the treatment.

[1]  P. Pandolfi,et al.  A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language? , 2011, Cell.

[2]  Li Gang,et al.  Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells , 2015, PloS one.

[3]  Bin Jiang,et al.  Pathway enrichment analysis approach based on topological structure and updated annotation of pathway , 2017, Briefings Bioinform..

[4]  Jing Zhao,et al.  Activation of p53 by MEG3 Non-coding RNA* , 2007, Journal of Biological Chemistry.

[5]  Chun Zhou,et al.  Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer , 2014, Tumor Biology.

[6]  Paul J van Diest,et al.  c-Jun activation is associated with proliferation and angiogenesis in invasive breast cancer. , 2006, Human pathology.

[7]  Hui Zhou,et al.  ChIPBase: a database for decoding the transcriptional regulation of long non-coding RNA and microRNA genes from ChIP-Seq data , 2012, Nucleic Acids Res..

[8]  Peter Angelos,et al.  The Breast–Thyroid Cancer Link: A Systematic Review and Meta-analysis , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[9]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[10]  Bo Zhang,et al.  Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer. , 2011, Carcinogenesis.

[11]  Hui Zhou,et al.  starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data , 2013, Nucleic Acids Res..

[12]  Gema Moreno-Bueno,et al.  Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. , 2008, Cancer research.

[13]  Yuh-Shan Jou,et al.  Xist reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression , 2016, Oncotarget.

[14]  Wei Chen,et al.  Sequence-based predictive modeling to identify cancerlectins , 2017, Oncotarget.

[15]  Ana Lluch,et al.  Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. , 2012, Cancer treatment reviews.

[16]  T. Libermann,et al.  Targeting transcription factors for cancer gene therapy. , 2006, Current gene therapy.

[17]  L. Mazzucchelli,et al.  Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Joseph G. Ibrahim,et al.  Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells , 2017, npj Breast Cancer.

[19]  Yan Huang,et al.  RNALocate: a resource for RNA subcellular localizations , 2016, Nucleic Acids Res..

[20]  Jian Chen,et al.  Genistein induces apoptosis by the inactivation of the IGF-1R/p-Akt signaling pathway in MCF-7 human breast cancer cells. , 2015, Food & function.

[21]  Enling Liu,et al.  Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. , 2015, International journal of clinical and experimental pathology.

[22]  Ping Tang,et al.  Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma: A 2015 Update. , 2016, Archives of pathology & laboratory medicine.

[23]  Wei Chen,et al.  MethyRNA: a web server for identification of N6-methyladenosine sites , 2017, Journal of biomolecular structure & dynamics.

[24]  Jian Chen,et al.  Calycosin and Genistein Induce Apoptosis by Inactivation of HOTAIR/p-Akt Signaling Pathway in Human Breast Cancer MCF-7 Cells , 2015, Cellular Physiology and Biochemistry.

[25]  Wei Chen,et al.  Predicting cancerlectins by the optimal g-gap dipeptides , 2015, Scientific Reports.

[26]  Hui Chen,et al.  Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma , 2014, Medical Oncology.

[27]  Andrea Salonia,et al.  Long non-coding RNAs as novel therapeutic targets in cancer. , 2016, Pharmacological research.

[28]  Hao Lin,et al.  Predicting the Organelle Location of Noncoding RNAs Using Pseudo Nucleotide Compositions , 2017, Interdisciplinary Sciences: Computational Life Sciences.

[29]  Zongze He,et al.  The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP. , 2017, Archives of biochemistry and biophysics.

[30]  C. Croce,et al.  MicroRNAs in cancer: small molecules with a huge impact. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Jun Li,et al.  Biomarkers , Genomics , Proteomics , and Gene Regulation miR-182 as a Prognostic Marker for Glioma Progression and Patient Survival , 2010 .

[32]  Paul L. Roebuck,et al.  TANRIC: An Interactive Open Platform to Explore the Function of lncRNAs in Cancer. , 2015, Cancer research.

[33]  Yan Cui,et al.  PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits , 2011, Nucleic Acids Res..

[34]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[35]  L. Lim,et al.  MicroRNAs in the miR-106b Family Regulate p21/CDKN1A and Promote Cell Cycle Progression , 2008, Molecular and Cellular Biology.

[36]  K. Tomczak,et al.  The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge , 2015, Contemporary oncology.

[37]  Yang Zhang,et al.  Expression levels of transcription factors c-Fos and c-Jun and transmembrane protein HAb18G/CD147 in urothelial carcinoma of the bladder , 2017, Molecular medicine reports.

[38]  Jindan Yu,et al.  LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer , 2015, Oncogene.

[39]  Wei Chen,et al.  RAMPred: identifying the N1-methyladenosine sites in eukaryotic transcriptomes , 2016, Scientific Reports.

[40]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[41]  Jingjuan Feng,et al.  miR-141-3p inhibits fibroblast proliferation and migration by targeting GAB1 in keloids. , 2017, Biochemical and biophysical research communications.

[42]  K. Chou,et al.  iRNA-Methyl: Identifying N(6)-methyladenosine sites using pseudo nucleotide composition. , 2015, Analytical biochemistry.

[43]  Peng Wang,et al.  Lnc2Cancer: a manually curated database of experimentally supported lncRNAs associated with various human cancers , 2015, Nucleic Acids Res..

[44]  S. Mangan,et al.  Structure and function of the feed-forward loop network motif , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Hongdong Li,et al.  Multi-level reproducibility of signature hubs in human interactome for breast cancer metastasis , 2010, BMC Systems Biology.

[46]  Yang Li,et al.  HMDD v2.0: a database for experimentally supported human microRNA and disease associations , 2013, Nucleic Acids Res..

[47]  Wei Jiang,et al.  Systematic dissection of dysregulated transcription factor–miRNA feed-forward loops across tumor types , 2015, Briefings Bioinform..

[48]  J. Weinstein,et al.  Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes , 2014, Oncotarget.

[49]  John Boyle,et al.  Cytoscape: a community-based framework for network modeling. , 2009, Methods in molecular biology.

[50]  Zheng Guo,et al.  Identification of potential therapeutic targets using breast cancer stroma expression profiling , 2016 .

[51]  Honglin Hu,et al.  rs11671784 G/A variation in miR-27a decreases chemo-sensitivity of bladder cancer by decreasing miR-27a and increasing the target RUNX-1 expression. , 2015, Biochemical and biophysical research communications.

[52]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[53]  Doron Lancet,et al.  MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search , 2016, Nucleic Acids Res..

[54]  Benno Schwikowski,et al.  Discovering regulatory and signalling circuits in molecular interaction networks , 2002, ISMB.

[55]  Mahdi Rezai,et al.  Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival , 2016, Journal of chemotherapy.

[56]  K. Chou,et al.  iRNA-PseColl: Identifying the Occurrence Sites of Different RNA Modifications by Incorporating Collective Effects of Nucleotides into PseKNC , 2017, Molecular therapy. Nucleic acids.

[57]  Yong Wang,et al.  miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation , 2016, Oncotarget.